Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carles Pericay

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Chemotherapy|April 22, 2010
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancerJosé-María Roca, Vicente Alonso, Carles Pericay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 TrialJoana Vidal, David Casadevall, Beatriz Bellosillo, et al.
The Oncologist|September 12, 2014
Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter TrialCarlos Fernandez-Martos, Gina Brown, Rafael Estevan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 31, 2023
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in SpainRocio Garcia-Carbonero, Beatriz González Astorga, Rosario Vidal Tocino, et al.
NEJM Evidence|February 6, 2024
<i>Nab</i>-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic CancerAlfredo Carrato, Roberto Pazo-Cid, Teresa Macarulla, et al.
JAMA Surgery|May 28, 2025
Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical TrialXavier Serra-Aracil, Carles Pericay, Ariadna Cidoncha, et al.
JAMA Oncology|August 30, 2019
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical TrialCarlos Fernández-Martos, Carles Pericay, Ferran Losa, et al.
Clinical Colorectal Cancer|March 17, 2012
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive TumorsManuel Benavides, Carles Pericay, Manuel Valladares-Ayerbes, et al.
International Journal of Colorectal Disease|April 23, 2026
Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study)Xavier Serra-Aracil, Anna Nonell, Cristina Gener-Jorge, et al.
Cancers|August 19, 2020
Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET StudyRuth Vera, María Luisa Gómez, Juan Ramón Ayuso, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Chemotherapy|April 22, 2010
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancerJosé-María Roca, Vicente Alonso, Carles Pericay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 TrialJoana Vidal, David Casadevall, Beatriz Bellosillo, et al.
The Oncologist|September 12, 2014
Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter TrialCarlos Fernandez-Martos, Gina Brown, Rafael Estevan, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 31, 2023
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in SpainRocio Garcia-Carbonero, Beatriz González Astorga, Rosario Vidal Tocino, et al.
NEJM Evidence|February 6, 2024
<i>Nab</i>-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic CancerAlfredo Carrato, Roberto Pazo-Cid, Teresa Macarulla, et al.
JAMA Surgery|May 28, 2025
Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical TrialXavier Serra-Aracil, Carles Pericay, Ariadna Cidoncha, et al.
JAMA Oncology|August 30, 2019
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical TrialCarlos Fernández-Martos, Carles Pericay, Ferran Losa, et al.
Clinical Colorectal Cancer|March 17, 2012
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive TumorsManuel Benavides, Carles Pericay, Manuel Valladares-Ayerbes, et al.
International Journal of Colorectal Disease|April 23, 2026
Chemoradiotherapy and transanal endoscopic surgery versus transanal endoscopic surgery alone in T1N0M0 rectal cancer: a multicenter, randomized, controlled, phase III clinical trial (TAUTEM-T1 study)Xavier Serra-Aracil, Anna Nonell, Cristina Gener-Jorge, et al.
Cancers|August 19, 2020
Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET StudyRuth Vera, María Luisa Gómez, Juan Ramón Ayuso, et al.
Pageof 7